- Home
- DHIL vs CTNM Comparison
DHIL vs CTNM Comparison
Compare DHIL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DHIL | CTNM |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.2M | 328.1M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DHIL | CTNM |
|---|---|---|
| Price | $114.98 | $12.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 27.2K | ★ 183.2K |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.21 | N/A |
| Revenue | ★ $149,665,296.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.67 | ★ N/A |
| Revenue Growth | ★ 2.65 | N/A |
| 52 Week Low | $114.11 | $3.35 |
| 52 Week High | $167.32 | $15.25 |
Technical Indicators
Market Signals| Indicator | DHIL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 60.94 |
| Support Level | $114.11 | $10.42 |
| Resistance Level | $117.70 | $11.43 |
| Average True Range (ATR) | 2.65 | 0.81 |
| MACD | -0.14 | 0.13 |
| Stochastic Oscillator | 7.94 | 74.66 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.